Jinyu Bio-technology Co., Ltd. (SHA:600201)
12.65
-0.35 (-2.69%)
Aug 21, 2026, 3:00 PM CST
Jinyu Bio-technology Revenue
Jinyu Bio-technology had revenue of 409.98M CNY in the quarter ending June 30, 2026, with 52.98% growth. This brings the company's revenue in the last twelve months to 1.53B, up 21.37% year-over-year. In the year 2025, Jinyu Bio-technology had annual revenue of 1.40B with 11.23% growth.
Revenue (ttm)
1.53B
Revenue Growth
+21.37%
P/S Ratio
8.99
Revenue / Employee
815.14K
Employees
1,881
Market Cap
13.79B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.40B | 140.96M | 11.23% |
| Dec 31, 2024 | 1.26B | -342.77M | -21.45% |
| Dec 31, 2023 | 1.60B | 69.56M | 4.55% |
| Dec 31, 2022 | 1.53B | -247.65M | -13.94% |
| Dec 31, 2021 | 1.78B | 194.41M | 12.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anhui Anke Biotechnology (Group) | 2.56B |
| Tibet Cheezheng Tibetan Medicine | 2.42B |
| Nanjing Vazyme Biotech | 1.41B |
| Shanghai Medicilon | 1.26B |
| Acrobiosystems | 887.21M |
| GemPharmatech | 878.13M |
| Chengdu Olymvax Biopharmaceuticals | 759.63M |
| Mabwell (Shanghai) Bioscience | 745.32M |